Researchers Uncover How Lecanemab Activates Brain's Immune Cells to Clear Alzheimer's Plaques
Key Insights
Scientists have demonstrated that lecanemab works by using its Fc fragment to activate microglia, the brain's immune cells, which then engulf and clear amyloid plaques in Alzheimer's disease.
The study used a mouse model with human microglia and showed that when the Fc fragment was disabled, the antibody could still bind plaques but failed to induce clearance.
Advanced transcriptomic analysis revealed that lecanemab triggers specific microglial gene expression programs linked to phagocytosis and plaque removal, particularly the SPP1 (search) gene encoding osteopontin.
Scientists have finally solved a key mystery surrounding lecanemab, the FDA-approved Alzheimer's drug, revealing that its therapeutic effects depend on activating the brain's immune cells through a specific molecular mechanism. The breakthrough research demonstrates that the antibody's Fc fragment acts as a crucial "molecular switch" that triggers microglia to clear toxic amyloid plaques.
Fc Fragment Essential for Therapeutic Action
The study, led by Prof. Bart De Strooper at the VIB-KU Leuven Center for Brain & Disease Research (search), used a specially designed mouse model populated with human microglia to investigate lecanemab's mechanism of action. The researchers found that while one end of the antibody binds to amyloid plaques, the Fc fragment engages receptors on microglia, prompting these immune cells to engulf and degrade the deposits.
"Our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer's disease. We show that the therapy's efficacy relies on the antibody's Fc fragment, which activates microglia to effectively clear amyloid plaques," says Dr. Giulia Albertini, co-first author of the study.
When researchers disabled the Fc fragment, the antibody still attached to plaques but crucially failed to induce any clearance, providing direct evidence that microglial activation is essential for therapeutic efficacy.
Molecular Mechanisms of Plaque Clearance
Using advanced single-cell and spatial transcriptomics techniques, the team identified specific cellular processes involved in plaque removal, including phagocytosis and lysosomal activity. These processes were only triggered when the Fc fragment was present and functional.
The analysis revealed that lecanemab induces a specific microglial gene expression program linked to phagocytosis, lysosomal degradation, and metabolic reprogramming. Among the most strongly upregulated genes was SPP1 (search), which encodes osteopontin, a protein shown to actively promote plaque clearance. These molecular changes were concentrated in microglia located near amyloid plaques, suggesting a highly localized and targeted immune response rather than widespread inflammation.
Selective Clearance Without Harmful Effects
Importantly, the study found that this microglial activation does not appear to trigger harmful side effects such as excessive synapse loss, an issue associated with some earlier antibody therapies. Instead, microglia selectively removed amyloid while preserving surrounding neural structures, and reductions in plaque burden were accompanied by decreases in neuritic damage.
"The fact that we used human microglia within a controlled experimental model was a major strength of our study. This allowed us to test the very antibodies used in patients and observe human-specific responses with unprecedented resolution," adds Magdalena Zielonka, co-first author.
Implications for Future Drug Development
The findings provide a clearer blueprint for Alzheimer's drug development, shifting focus from simply targeting amyloid to precisely controlling how the brain's immune system responds. The research suggests that future therapies may be able to activate microglia directly without relying on antibodies.
"This opens doors to future therapies that may activate microglia without requiring antibodies. Understanding the importance of the Fc fragment helps guide the design of next-generation Alzheimer's drugs," concludes Prof. Bart De Strooper.
However, challenges remain, as the same Fc-mediated immune engagement that drives plaque clearance may also contribute to adverse effects such as inflammation or vascular complications. The authors suggest that fine-tuning Fc interactions or bypassing antibodies altogether by directly stimulating microglial pathways could offer safer, more effective strategies.
The research addresses a critical need in Alzheimer's treatment, as more than 55 million people worldwide live with the disease, which is driven by the buildup of amyloid plaques that damage neurons and eventually lead to dementia. While microglia naturally gather around these plaques, they are typically unable to remove them effectively, making the restoration of this immune function a key therapeutic target.